AN ACT to amend Tennessee Code Annotated, Title 3; Title 4; Title 5; Title 6; Title 7; Title 8; Title 10; Title 12; Title 29; Title 35; Title 36; Title 37; Title 39; Title 40; Title 41; Title 42; Title 45; Title 47; Title 49; Title 50; Title 52; Title 53; Title 56; Title 58; Title 63; Title 67; Title 68 and Title 71, relative to health insurance.

Description

Fiscal Summary NOT SIGNIFICANT Bill Summary ON APRIL 15, 2026, THE HOUSE ADOPTED AMENDMENT #1 AND PASSED HOUSE BILL 2503, AS AMENDED. AMENDMENT #1 rewrites the bill to, instead, authorize a health insurance entity to offer a short-term limited-duration plan and hospital indemnity coverage on the marketplace. SHORT-TERM LIMITED-DURATION PLAN This amendment authorizes a health insurance entity to offer a short-term limited-duration plan if the plan complies with the duration limitations or requirements imposed by federal law for a short-term limited-duration plan to be offered on the marketplace, and provides no less than the following minimum coverage and benefits:  A per person deductible of no more than $10,000 per term. A per family deductible for all covered family members of no more than $10,000 per term. A coinsurance of no more than 20% per term. A maximum out-of-pocket coinsurance of no more than $5,000 per term. A maximum benefit, per person, per term, of one million dollars. Coverage with a copay of no more than $50 per person, per term, for a visit with a physician for the enrollee's history and exam only. Coverage with a copay of no more than $50 per person, per term, for an urgent care visit. A copay of no more than 20% of the reasonable and customary charges for: (i) a preventative care visit, (ii) an emergency room visit for accident or illness, (iii) an inpatient hospital service, (iv) an outpatient surgery, (v) a lab, and (vi) an x-ray. Four tiers of pharmacy benefits for outpatient prescription drugs as follows: (i) for the first tier, coverage of preferred generic drugs with a copay of no more than $25 and no deductible, (ii) for the second tier, coverage of generic drugs, (iii) for the third tier, coverage of preferred brand drugs, and (iv) for the fourth tier

Subjects

Progress

1. IntroducedFeb 2, 2026
2. Passed the first chamberFeb 5, 2026
3. Sent to committeeFeb 5, 2026
4. Sent to committeeMar 10, 2026
5. Sent to committeeApr 7, 2026